Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMYMP) Divestments (2016 - 2025)

Historic Divestments for Bristol Myers Squibb (BMYMP) over the last 17 years, with Q4 2025 value amounting to $279.0 million.

  • Bristol Myers Squibb's Divestments fell 1621.62% to $279.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.1 billion, marking a year-over-year decrease of 254.78%. This contributed to the annual value of $1.1 billion for FY2025, which is 254.78% down from last year.
  • Per Bristol Myers Squibb's latest filing, its Divestments stood at $279.0 million for Q4 2025, which was down 1621.62% from $279.0 million recorded in Q3 2025.
  • Bristol Myers Squibb's 5-year Divestments high stood at $490.0 million for Q4 2022, and its period low was $178.0 million during Q4 2021.
  • Its 5-year average for Divestments is $256.6 million, with a median of $242.0 million in 2023.
  • Its Divestments has fluctuated over the past 5 years, first soared by 17528.09% in 2022, then crashed by 5081.63% in 2023.
  • Over the past 5 years, Bristol Myers Squibb's Divestments (Quarter) stood at $178.0 million in 2021, then skyrocketed by 175.28% to $490.0 million in 2022, then plummeted by 50.82% to $241.0 million in 2023, then surged by 38.17% to $333.0 million in 2024, then fell by 16.22% to $279.0 million in 2025.
  • Its last three reported values are $279.0 million in Q4 2025, $279.0 million for Q3 2025, and $270.0 million during Q2 2025.